Glenmark enters into licensing agreement to commercialise dry powder inhaler

Glenmark Pharmaceuticals Ltd. has announced that Glenmark Pharmaceuticals Europe has entered into a strategic, exclusive licensing agreement for marketing generic tiotropium bromide dry powder inhaler (DPI) in Western Europe. Tiotropium bromide DPI is a generic version of Boehringer Ingelheim’s Spiriva Handihaler. The product is used in the treatment of chronic obstructive pulmonary disease (COPD).

This is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/Salmeterol DPI. “Respiratory is a core area of focus for Glenmark and this deal shows our commitment to increase product offerings within this segment. There is significant opportunity in the inhalers market and we believe that this deal will give further impetus to Glenmark’s growth in Europe,” said Mr. Achin Gupta, EVP & Business Head of Europe and Latin America, Glenmark Pharmaceuticals Ltd. According to data from IQVIA, Boehringer Ingelheim’s Spiriva Handihaler recorded sales of US$724-mn in the EU in the 12-month period ended March 2018.